EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France

Fanny Porte, Anna Granghaud, Jane Chang, Mairead Kearney, Aya Morel, Ingrid Plessala iD, Hélène Cawston, Julie Roiz, Ying Xiao, Marie-Noelle Solbes, Prisca Lambert, Alain Ravaud und 3 weitere

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0302548 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Fanny Porte und 14 weiteren Autor:innen. Beteiligte Einrichtung: Health Economics Department, Merck Santé S.A.S., Lyon, France. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Cost-Benefit Analysis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Santé S.A.S, an affiliate of Merck KGaA, Darmstadt, Germany, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study evaluated the cost-effectiveness of avelumab first-line (1L) maintenance therapy plus best supportive care (BSC) versus BSC alone for adults with locally advanced or metastatic urothelial carcinoma (la/mUC) that had not progressed following platinum-based chemotherapy in France.

Methods

A three-state partitioned survival model was developed to assess the lifetime costs and effects of avelumab plus BSC versus BSC alone. Data from the phase 3 JAVELIN Bladder 100 trial (NCT02603432) were used to inform estimates of clinical and utility values considering a 10-year time horizon and a weekly cycle length. Cost data were estimated from a collective perspective and included treatment acquisition, administration, follow-up, adverse event–related hospitalization, transport, post-progression, and end-of-life costs. Health outcomes were measured in quality-adjusted life-years (QALYs) and life-years gained. Costs and clinical outcomes were discounted at 2.5% per annum. Incremental cost-effectiveness ratios (ICERs) were used to compare cost-effectiveness and willingness to pay in France. Uncertainty was assessed using a range of sensitivity analyses.

Results

Avelumab plus BSC was associated with a gain of 2.49 QALYs and total discounted costs of €136,917; BSC alone was associated with 1.82 QALYs and €39,751. Although avelumab plus BSC was associated with increased acquisition costs compared with BSC alone, offsets of −€20,424 and −€351 were observed for post-progression and end-of-life costs, respectively. The base case analysis ICER was €145,626/QALY. Sensitivity analyses were consistent with the reference case and showed that efficacy parameters (overall survival, time to treatment discontinuation), post-progression time on immunotherapy, and post-progression costs had the largest impact on the ICER.

Conclusions

This analysis demonstrated that avelumab plus BSC is associated with a favorable cost-effectiveness profile for patients with la/mUC who are eligible for 1L maintenance therapy in France.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCost-Benefit AnalysisHumansFranceMaleFemaleUrinary Bladder NeoplasmsQuality-Adjusted Life YearsAgedMiddle AgedAdultCarcinoma, Transitional CellNeoplasm MetastasisUrologic NeoplasmsMaintenance Chemotherapy

Substanzen

avelumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Health Economics Department, Merck Santé S.A.S., Lyon, France.
  • Health Economics department, Pfizer S.A.S., Paris, France.
  • Health Economics department, Pfizer, New York, NY, United States of America.
  • Global Value Demonstration, Market Access and Pricing, The Healthcare Business of Merck KGaA, Darmstadt, Germany.
  • Health Economics & Market Access (HEMA), Amaris Consulting, Paris, France.
  • Health Economics, Evidera, London, United Kingdom.

ORCID-Profile: Ingrid Plessala

Förderung

  • Merck Santé S.A.S, an affiliate of Merck KGaA, Darmstadt, Germany
  • Pfizer

Zitieren

APA

Porte, F., Granghaud, A., Chang, J., Kearney, M., Morel, A., Plessala, I., Cawston, H., Roiz, J., Xiao, Y., Solbes, M. N., Lambert, P., Ravaud, A., Loriot, Y., Thiery-Vuillemin, A., & Lévy, P. (2024). Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France. PLOS ONE. https://doi.org/10.1371/journal.pone.0302548

Vancouver

Porte F, Granghaud A, Chang J, Kearney M, Morel A, Plessala I, et al. Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France. PLOS ONE. 2024. doi:10.1371/journal.pone.0302548

BibTeX
@article{Porte2024,
  author = {Porte, Fanny and Granghaud, Anna and Chang, Jane and Kearney, Mairead and Morel, Aya and Plessala, Ingrid and Cawston, Hélène and Roiz, Julie and Xiao, Ying and Solbes, Marie-Noelle and Lambert, Prisca and Ravaud, Alain and Loriot, Yohann and Thiery-Vuillemin, Antoine and Lévy, Pierre},
  title = {Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0302548}
}
Kostenlos starten →